Two‐stage cost‐sensitive clinical decision support system for detecting Alzheimer’s disease

A two‐stage clinical decision support pipeline was developed to first recommend individuals for further testing based on easily administered screening tests, followed by a more robust identification of impairment based on additional cognitive testing and neuroimaging. The ultimate goal of the pipeline is to recommend further in‐depth diagnostic assessment for those identified as “likely impaired” and reduce the incidence of healthy controls needing to undergo costly diagnostic assessments.